Lifeboat Foundation

Several Covid-19 vaccines under development in Israel hold out promise for their ability to protect against variants of the virus that are challenging existing vaccines.

Back in May 2020, research groups across the world were racing to formulate vaccines against the SARS-CoV-2 coronavirus.

Realizing it was not going to win that race, Israel purchased millions of Pfizer-BioNTech and Moderna mRNA vaccines from the United States and led the world in getting eligible citizens vaccinated.… See more.

Continue reading “Will an Israeli vaccine be the solution to new variants?” »

LifeArc scientists, in collaboration with researchers in the UK and Germany, have developed a promising new approach to potentially treat Alzheimer’s disease – and also vaccinate against it.

Both the antibody-based treatment and the protein-based vaccine developed by the team reduced Alzheimer’s symptoms in mouse models of the disease. The research is published today in Molecular Psychiatry.

LifeArc and researchers in the UK & Germany have developed a promising new approach to potentially treat Alzheimer’s.

Continue reading “New approach provides potential vaccine and treatment for Alzheimer’s” »

The development of a genetic code expansion-based system enables fast protein expression in response to a noncanonical amino acid. The system was implanted into diabetic mice to rescue hyperglycemia with oral delivery of the amino acid.

The new form of war is already here and most don’t realize it.

Thanks to Hone for sponsoring this video! Go to https://honehealth.com/thoughty2 to get your home assessment test and a doctor’s consultation for only $45!

Continue reading “Why We Have No Way to Fight Against North Korean Hackers” »

Researchers have identified a version of a gene that doubles a person’s risk of severe COVID-19 and doubles the risk of death from the disease for people under 60.

The new Covid pills from Merck and Pfizer offer a ton of promise. But there’s plenty we still don’t know about how well they work.

The new Covid pills from Merck and Pfizer offer a ton of promise. But there’s plenty we still don’t know about how well they work.

The last year has been a story of triumph in the vaccine world, with the rapid development of two highly successful vaccines for Covid-19, one developed by Moderna and the other by Pfizer and BioNTech. Now that flu season is approaching, why are we still using 50-year-old technology for the flu vaccine?

The reason the Covid-19 vaccines were developed so quickly is that they used a new, much faster and easier-to-create type of vaccine technology, based on messenger RNA, or mRNA. What’s even more exciting is that we now have an overwhelming amount of evidence, from real-world experience, that these vaccines are remarkably safe and effective.

Now, anti-vaxxers and the “vaccine hesitant” are claiming they don’t trust the vaccine because it was developed too fast. That’s ridiculous: the real reason they don’t trust the vaccine is because they’re consuming a steady diet of anti-vaccine nonsense, promoted by a combination of right-wing media and the Disinformation Dozen (who include left-wing as well as right-wing zealots). But let’s not go down that rabbit hole today.

I may have already posted about this, but this is more data from The Lancet.

Background.

Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we aimed to assess the efficacy of fluvoxamine versus placebo in preventing hospitalisation defined as either retention in a COVID-19 emergency setting or transfer to a tertiary hospital due to COVID-19.

Continue reading “Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial” »

Creating a world where no woman has to die giving life — temitayo erogbogbo, global advocacy director, MSD for mothers, merck sharp & dohme.

Mr. Temitayo (Tayo) Erogbogbo, is Global Advocacy Director of MSD for Mothers (https://www.msdformothers.com/), at Merck Sharp & Dohme.

Continue reading “Mr. Temitayo Erogbogbo, Global Advocacy Director, MSD for Mothers (Merck Sharp & Dohme)” »